The new proposed rule for the US Food and Drug Administration’s oversight of laboratory developed tests (LDTs) can’t solve everything, Becton Dickinson’s Ami Simunovich said during AdvaMed’s Medtech Conference on 9 October.
Simunovich serves as the chief quality and regulatory officer and public affairs at BD. Based on her regulatory experience, she said that legislation is the way to reform the diagnostic...